Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327824 | 0.90 | MAPK1 (0.51) | HPGDMAPK1KDM4EALDH1A1NPC1 | |
| SCHEMBL1587865 | 0.87 | HPGD (0.50) | HPGDMAPK1KDM4EALDH1A1NPC1 | |
| SCHEMBL2001834 | 0.87 | NPSR1 (0.50) | HPGDMAPK1KDM4EALDH1A1NPC1 | |
| SCHEMBL12124264 | 0.83 | POLB (0.61) | HPGDMAPK1KDM4EALDH1A1NPC1 | |
| SCHEMBL16011515 | 0.83 | HDAC1 (0.61) | HPGDMAPK1KDM4EALDH1A1RAB9A | |
| SCHEMBL2201378 | 0.81 | HDAC1 (0.68) | HPGDMAPK1KDM4EALDH1A1NPC1 | |
| SCHEMBL12313386 | 0.81 | HPGD (0.56) | HPGDMAPK1KDM4EALDH1A1NPC1 | |
| SCHEMBL6455155 | 0.80 | HDAC3 (0.65) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL8593304 | 0.80 | SMN1; SMN2 (0.46) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL70027 | 0.80 | NPSR1 (0.67) | HPGDMAPK1KDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904488-B1 | PYRAZOLE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7968542-B2 | Thiophene compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7960425-B2 | Pyrazole compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20110092496-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20090131676-A1 | PYRAZOLE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1904472-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904488-A1 | PYRAZOLE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007011056-A1 | PYRAZOLE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010954-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | HPGD 2277/4885MAPK1 853/4885KDM4E 3583/4885 |
| US-20110092496-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | HPGD 2277/4885MAPK1 853/4885KDM4E 3583/4885 |
| US-20090131676-A1 | PYRAZOLE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | MPL, THPO, TEK | HPGD 1155/4885MAPK1 446/4885KDM4E 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.